In the twelve months that form 2022, medicines aimed at diabetes diseases and cardiovascular pathologies have been the drugs that have most invoiced in Spanish pharmacies.Specifically, five antidiabetic therapies, three antithrombotic, one for osteoporosis and one for heart failure lead the ranking, according to data from the IQVIA consultant.
The medicine that heads the list is Eliquis, an anticoagulant of the pharmaceutical Bristol Myers Squibb.Until May 2022, last data that is known, the drug records sales of 118.6 million euros, that is, 17.1% more compared to the previous year in Spanish pharmacies.It is followed by Ozempic de Novo Nordisk with 83.40 million euros, Xarelto de Bayer with 80.40 million, Lilly Trulicity with 64.30 million and Jardiance of Boehringer with 57.40 million.
The treatments that occupy the second position, that is, that of the Danish company;And the fourth position, that of the American company, suffer supply problems due to demand.In October 2022, the Spanish Agency for Medicine and Health Products (AEMPS) together with the two companies warned of the lack of both medications, together with Bydureon de Astrazeneca, both for 2022 and 2023 to start new treatments.They asked health professionals not to start new treatments with these drugs
From fifth place, several medications have changed position.In position number six there is Prolia, an anticoagulant of the Pharmaceutical Amgen (the company recently made with the Irish Horizon Therapeutics), which has risen two positions since May.In the first five months of 2022 he billed 50.50 million.It is followed by Lixiana of the company Daiichi Sankyo that registered in sales until May 58.60 million.This has dropped two positions since then.
These are not the only medications in which their position has varied in the ranking.Entrest of Novartis today is in number eight position, one more than in the first five months of 2022. He until then invoiced 53.10 million euros.It is followed in ninth Synjardy position, marketed by Boehringer and Lilly, which registered sales of 45.70 million until May of that year.The diabetes medicine has uploaded a position since that time.
Ultimately on the list is occupied by Toujeo de Sanofi, it is a drug for diabetes.Until May 2022 he billed 46.30 million euros and was the ninth in the ranking.On the other hand, in terms of indications, Bristol Myers Squibb is the first on the list of those who go to anticoagulation and that of Novo Nordisk in regard to those that are prescribed for diabetes.
